الفهرس 
EARLY AND LOCALLY ADVANCED BREAST CANCER MANAGEMENTOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
Background: Breast cancer is the most common cnacer in women, COVID-19 pandemic impacted cancer patients as they are immunocompromised due to their disease and cytotoxic treatments. This study aims to assess the efficacy and safety of anti SARS COV 2 vaccines in breast cancer patients by evaluating anti spike antibodies. Our population consisted of 120 female patients diagnosed with early and locally advanced breast cancer.
Patients and Methods: All on oncological systemic therapy. Sixty vaccinated and 60 unvaccinated against COVID-19. The cutoff value of antispike antibody is 50 BAL/mL (≥50 seropositive, <50 seronegative).
Results: Out of 120 patients, anti-SARS COV-2 Antibody seropositivity was found to be 48 vs. 58 pts (80% vs. 96.7%) in non vaccinated Vs. Vaccinated patients (P-value =0.0046), which was statistically significant. The median titre in both groups was found to be 1434.5 vs. 2500, (P=0.0026). Only 26 patients had covid infection, non vaccinated Vs. Vaccinated: 21 vs. 5 pts (35% vs. 8.3 % , P = 0.0004). In the sixty vaccinated patients , mild local adverse events were reported such as warmness at site of injection site in 17 patients, (28.3%), Pain 11 (18.3%), Swelling 11 (18.3%), Itch 8 (13.3%), and Redness 6 (60%). The patients experienced mild systemic adverse events, Fatigue 28 (46.7%), Myalgia/arthralgia 17(28.3%), headache 2 (3.3%), and fever 16 (26.7%).
Conclusion: Anti SARS COV2 vaccines are effective and safe in localized breast cancer patients on systemic therapy.